Project Grant HT9425261E081
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.25 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026, with a completion date of April 30, 2029. The grant funds research to develop first-in-class protein degraders targeting PTK6 (protein tyrosine kinase 6) as a therapeutic approach for triple-negative breast cancer. This research directly aligns with the DHA's...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $1,249,998 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2029. The award supports research focused on targeting KDM5 histone demethylases as a therapeutic approach to treat breast cancer. This research falls within the DHA's broader mission to advance innovative biomedical solutions...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.23M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2028. The award supports biomarker development research focused on refining an individualized risk-adapted approach to bladder-sparing treatment for muscle-invasive bladder cancer. This research initiative aims to advance clinical decision-making and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $507,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2027. The award supports research to investigate tumor-intrinsic epigenetic mechanisms that modulate antitumor immune responses in metastatic prostate cancer. This research initiative advances the DHA's mission to transform healthcare...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai (ISMMS) received a $505,270 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with a completion date of September 29, 2027. The award supports research investigating the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer to develop therapeutic strategy. This research aligns with the...
- Grant Award Summary Icahn School of Medicine at Mount Sinai received a $633,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award funds research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This research contributes to the DHA's broader mission of transforming healthcare for...
- Federal Project Grant Summary Icahn School of Medicine at Mount Sinai received a $633,750 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a completion date of July 31, 2028. The grant supports research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This three-year research initiative aligns with the Defense Health...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $591,500 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2027. The award supports research titled "Decoding the Tumor Microenvironment Remodeling of Cancer Vaccine Treatment in Pleural Mesothelioma," to be conducted at the institution's New York, NY location. This project...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $2.18M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to investigate metabolites and metabolic pathways associated with Crohn disease risk. The award, dated June 1, 2025, supports a four-year research initiative extending through June 30, 2029, conducted at the institution's New York campus. This biomedical research project aligns...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $3.3M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Leveraging Personalized Stem Cell Therapy to Overcome Airway Reconstruction." The four-year award, which commenced June 1, 2025 and concludes May 31, 2029, supports advanced biomedical research aimed at developing innovative therapeutic...
The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.25M project grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026 through April 30, 2029. The award supports research and development services focused on first-in-class degraders targeting oncogenic PTK6 (protein tyrosine kinase 6) in triple-negative breast cancer. This three-year research initiative aligns with the DHA's mission to transform healthcare for service members and the American public through innovative biomedical solutions addressing critical health challenges, with particular emphasis on cancer research and precision medicine approaches. The research conducted at the New York-based institution will advance therapeutic development and translational research activities in oncology, contributing to the broader federal portfolio of cancer immunotherapy and breast cancer research extensions supported under the Military Medical Research and Development program. As a frequently awarded recipient under DHA programs with substantial experience executing complex biomedical research initiatives, Mount Sinai will deliver research outputs designed to support military health priorities while advancing public health objectives through hypothesis-driven investigation of novel degrader-based therapeutic strategies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 5/1/26 |